EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
March 18, 2026
Sterile Hyaluronic Acid: Powering HA-based Next Generation of Medical Innovation
Sterile HA production unit
HTL Biotechnology has inaugurated this year a new sterile HA production unit. Importantly, HTL Biotechnology is today the only producer in Europe capable of delivering sterile hyaluronic acid, reinforcing our position as a strategic partner for healthcare innovators. By offering this unique material, HTL Biotechnology empowers its partners to innovate faster and safer, shaping the future of biopolymer-based medicine.
Hyaluronic Acid: A Cornerstone of Modern Medicine
Hyaluronic acid (HA), or sodium hyaluronate, has established itself as a cornerstone molecule across multiple medical fields. Its unique properties such as biocompatibility, hydrophilicity and biodegradability make it indispensable in ophthalmology, rheumatology, and medical aesthetic. Furthermore, its potential is widely studied today in drug delivery.
For decades, HTL Biotechnology has supplied pharmaceutical-grade HA of exceptional purity, with very low protein and endotoxin levels, produced under strict GMP standards. This HA is the benchmark raw material for countless pharmaceutical and medical device formulations worldwide.
Powering Next-Gen Drug Delivery system with Sterile HA
HTL’s pharmaceutical-grade HA is the industry standard for all of medical applications and continues to be a biomaterial that drives medical innovation.
Sterile HA is a complementary solution for highly specific, innovative projects that require aseptic HA. Its main advantage is that it enables combination with thermosensitive actives or biomolecules that would be degraded by heat-based sterilization. It removes the need for additional sterilization steps and paves the way for advanced drug delivery systems.
With over 30 years of expertise and excellence in pharmaceutical-grade HA, and now sterile HA, HTL Biotechnology is the trusted partner for supporting healthcare innovation.
To see our most recent news,
follow us on LinkedIn
Read more
blog posts from us
-
September 2, 2026Biopolymers for Ophthalmic Drug Delivery: The Example of Ophthalmic Inserts in Glaucoma Treatment
Glaucoma is currently one of the leading causes of irreversible vision loss worldwide. This chronic disease is characterized by progressive damage to the optic nerve, with elevated intraocular pressure being the main modifiable risk factor for disease development and progression. Management relies on the daily administration of pressure-lowering treatments in the form of eye drops to slow disease progression. Although these treatments have demonstrated their efficacy, their long-term use remains challenged by a major issue: treatment adherence, due in part to the physiological limitations of conventional ocular drug administration.
In response to these limitations, the development of new ophthalmic drug delivery technologies aims to improve drug residence time in the eye and ensure a more consistent release of the active pharmaceutical ingredient. Among these innovations, ophthalmic inserts are emerging as a promising technology. [1]
-
July 15, 2026Three Biomolecules Driving the Future of Skin Quality
Skin quality has become one of the main focuses of modern aesthetic medicine. While traditional treatments have often aimed to correct visible signs of ageing, today’s regenerative approaches seek to improve the skin itself by supporting hydration, structure and tissue regeneration.
-
June 25, 2026Expert spotlight : Hyaluronic Acid cross-linking: A key determinant of filler performance
Hyaluronic acid (HA) has become the dominant biomaterial in injectable soft tissue augmentation, with millions of treatments performed annually worldwide. As a naturally occurring glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine, native HA possesses exceptional biocompatibility, hygroscopicity, and viscoelastic properties. However, in its unmodified state, HA is rapidly degraded in vivo by endogenous hyaluronidases and reactive oxygen species, with a tissue half-life measured in hours to days. [1,2]
To overcome this limitation and create materials suitable for lasting soft tissue correction, HA must be chemically cross-linked. This process transforms a fluid polysaccharide solution into a structured hydrogel with tuneable mechanical and biological properties. The chemistry of cross-linking is, in many respects, the defining step that determines how a dermal filler will perform in the hands of a clinician and in the tissues of a patient. [2,3]